Pfizer and Merck KGaA are officially fourth to market with their checkpoint inhibitor avelumab—but first with to target a rare, aggressive form of skin cancer.
SkinJect, a Pittsburgh-based device company, said it reached a deal with the University of Pittsburgh to license a minimally invasive treatment for common forms of nonmelanoma skin cancer, basal cell and squamous cell carcinoma.